Skip to content
Medx

Tag: Non small cell lung cancer

Explore our medication guides and pharmacology articles within this category.

What is rilvegostomig? An In-Depth Pharmacological Review

•
4 min read
In non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), rilvegostomig has demonstrated an objective response rate (ORR) of 61.8% [1.5.6]. This article explores the question: What is rilvegostomig and its role in modern oncology?

When did Abraxane come out?: A Timeline of its FDA Approval and Expansion

•
4 min read
Abraxane, a unique albumin-bound paclitaxel formulation, received its first U.S. Food and Drug Administration (FDA) approval on January 7, 2005, for the treatment of metastatic breast cancer. This initial approval answered the pivotal question, "When did Abraxane come out?", paving the way for its use in other cancer treatments in the years that followed.